Joe discusses the limitations of direct-to-consumer genetic tests, highlighting how they often fail to provide actionable health insights and can lead to unnecessary anxiety. Nathalie emphasizes the importance of understanding the business models behind these tests, noting that while some companies collect data for drug discovery, others focus on offering personalized health recommendations. Together, they explore the potential benefits of using data responsibly to empower individuals in managing their health.
